Development, verification, and comparison of a risk stratification model integrating residual cancer burden to predict individual prognosis in early-stage breast cancer treated with neoadjuvant therapy-Reference-Cited by-同舟云学术

Development, verification, and comparison of a risk stratification model integrating residual cancer burden to predict individual prognosis in early-stage breast cancer treated with neoadjuvant therapy

Published:2021-10 Issue:5 Volume:6 Page:100269
ISSN:2059-7029
Container-title:ESMO Open
language:en
Short-container-title:ESMO Open

Author:

Hou N.,Wu J.,Xiao J.,Wang Z.,Song Z.,Ke Z.,Wang R.,Wei M.,Xu M.,Wei J.,Qian X.,Xu X.,Yi J.,Wang T.,Zhang J.,Li N.,Fan J.,Hou G.,Wang Y.,Wang Z.,Ling R.

Funder

National Natural Science Foundation of China

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference46 articles.

1. Breast cancer statistics, 2019;DeSantis;CA Cancer J Clin,2019

2. Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United States;Mougalian;Cancer,2015

3. Neoadjuvant therapy as a platform for drug development and approval in breast cancer;Bardia;Clin Cancer Res,2013

4. Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657);Campbell;Breast Cancer Res Treat,2017

5. Validation of residual proliferative cancer burden as a predictor of long-term outcome following neoadjuvant chemotherapy in patients with hormone receptor-positive/human epidermal growth receptor 2-negative breast cancer;Miglietta;Oncologist,2020

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nomograms for the Prognosis Prediction Model of Early-stage Triple- negative Breast Cancer - Based on SEER Database;2024-08-27

2. Risk of Recurrence in Patients With HER2+ Early-Stage Breast Cancer: Literature Analysis of Patient and Disease Characteristics;Clinical Breast Cancer;2023-06

3. Advances in the diagnosis and prognosis of minimal residual lesions of breast cancer;Pathology - Research and Practice;2023-05

4. Establishment and verification of a nomogram to predict tumor-specific mortality risk in triple-negative breast cancer: a competing risk model based on the SEER cohort study;Gland Surgery;2022-12

5. Pathological response of breast cancer of patients treated by neoadjuvant chemotherapy and correlation with survival. A perspective of real-world pathology;2022-10-24